Treatment of Haemophilus influenzae Pneumonia in Adult Inpatients with Severe Community-Acquired Pneumonia
This protocol applies to adult inpatients with severe community-acquired pneumonia (CAP) due to Haemophilus influenzae who do not carry risk factors for MRSA or Pseudomonas aeruginosa.
Clinical Scenario
Severity is established by one major or three or more minor 2007 IDSA/ATS criteria. This population has no prior respiratory isolation of MRSA or P. aeruginosa and no recent hospitalisation with receipt of parenteral antibiotics within the preceding 90 days.
Treatment Approach (partial summary)
Guideline-recommended therapy centres on a β-lactam-based combination — paired with either a macrolide or a respiratory fluoroquinolone. Treatment continues until clinical stability is reached and for at least a minimum course length. The full regimen, agents, and sequencing are available in the complete protocol.
Clinical Goals
The target endpoint is clinical stability: resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, temperature), ability to eat, and normal mentation. Most patients achieve this within 48 to 72 hours.
References
- DOI: 10.1164/rccm.201908-1581ST
- In inpatient adults with severe CAP (see Table 1) without risk factors for MRSA or P. aeruginosa, we recommend (Table 4) (note, specific agents and doses are the same as 9.1):
- a b-lactam plus a macrolide (strong recommendation, moderate quality of evidence); or
- a b-lactam plus a respiratory fluoroquinolone (strong recommendation, low quality of evidence).
- We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).
- As most patients will achieve clinical stability within the first 48 to 72 hours, a total duration of therapy of 5 days will be appropriate for most patients.
View source ↗